Ps1535 Autologous Stem Cell Transplant Followed by Post‐transplant Immunotherapy With Nivolumab and Unselected Autologous Lymphocytes Infusion as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma

Abstract

Methods: Three cohorts (200 mg QD [n = 17], 200 mg BID [n = 16] and 400 mg QD [n = 21]) were enrolled sequentially. The primary endpoint is the overall response rate, defined per the 2014 NIH Consensus criteria. Results: Patients enrolled in all three cohorts received a median of 2 prior lines of cGVHD therapy. The median corticosteroid dose at baseline was 0.19 mg/kg/day. The most frequently involved organs were eyes (78%), skin (74%), mouth (65%), joints/fascia (61%) and lungs (31%). Forty-eight percent (48%) of patients had involvement of ≥ 4 organs. As of